Christopher Stockdale

Christopher Stockdale practices at Redding Urologic Associates in Redding, California.

Christopher Stockdale's NPI, 1528453594, was assigned on April 6, 2015. Christopher Stockdale graduated from Loyola University Chicago Stritch School of Medicine in 2015. Christopher Stockdale holds Montana license 87703.

Christopher Stockdale's primary practice is Redding Urologic Associates, at 2626 Edith Ave Suite C Suite C, Redding, CA 96001-3056. The practice phone is (530) 241-3316.

Christopher Stockdale's primary practice is Redding Urologic Associates in Redding, California. Christopher Stockdale is also affiliated with Mercy Medical Center Redding. The medical group on file is Redding Urologic Associates. Dmand AI also links Christopher Stockdale to 4 more hospitals, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Christopher Stockdale practices, 6 sites in all. Vendor and product names are available with a free account.

Urology is Christopher Stockdale's primary specialty in the NPI Registry, under taxonomy code 208800000X. Christopher Stockdale is board certified in urology by the American Board of Urology. Dmand AI has Christopher Stockdale's licenses on file in 4 states: Montana, Maine, California and Wyoming.

Dmand AI lists bladder disease, enlarged prostate, enlarged prostate transurethral surgery (TURP), erectile dysfunction, kidney cysts, kidney removal surgery, kidney stone disease and prostate cancer among the conditions Christopher Stockdale treats.

CMS data shows 9,861 Medicare services from Christopher Stockdale across 36 procedure codes in 2024, for 1,091 Medicare patients. Medicare paid $493,090 for them.

CMS counts 1,091 Medicare patients who saw Christopher Stockdale in 2024. The largest group is 65 to 74, with 457 patients. 75% of them have high cholesterol, and 73% have high blood pressure. 19% are also on Medicaid. Their average risk score is 1.29, where 1.00 is the Medicare average.

Across all payers, Dmand AI patient panel data puts Christopher Stockdale's median patient age at 68, with 22% women.

In 2024, Christopher Stockdale wrote 1,494 Medicare Part D claims for 424 patients. 94% of them were for generic drugs. CMS names the drug for 1,371 of them, across 19 drugs with 11 or more claims each, at $103,118 in total drug cost. In 2023, CMS named 1,040 claims across 13 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 100 out of 100 for Christopher Stockdale for performance year 2024, reported as part of a group. Christopher Stockdale accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS counts 42 procedures of prostate resection by Christopher Stockdale, more than 96% of the clinicians it reports for that procedure.

CMS Open Payments shows 33 general payments to Christopher Stockdale from 13 drug and device companies from 2021 to 2025. Food and beverage make up the largest share, 92% of the total. Calyxo, Inc. paid the most, $361.

Christopher Stockdale graduated from Loyola University Chicago Stritch School of Medicine in 2015.

Christopher Stockdale is in network with 9 carriers, including Aetna, Elevance and United Healthcare. Medicare plans come from the most carriers, 7. Check the plan with the practice before a visit.